January 1, 2003Drug Development Research

1,4‐dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state‐dependent interactions, channel isoforms, and other factors

View Full Paper

Ask AI

Bookmark

Design

Review

Authors

DTDavid J. TriggleOregon National Primate Research Center

Discussion

Member takes

Implication

Does not alter CCB prescribing; leaves open isoform-specific targeting for future trials.

Structured PICO

Intervention

1,4-dihydropyridine calcium channel antagonists

The tissue selectivity and clinical effects of 1,4-dihydropyridine calcium channel antagonists are driven by complex interactions involving pharmacokinetics, channel states, and specific isoforms.

Cite This Study

David J. Triggle (2003) studied this question.

synapsesocial.com/papers/6a7f8d3fa7259c59cfca7e40 https://doi.org/10.1002/ddr.10124

View Full Paper

Ask AI

Bookmark

1,4‐dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state‐dependent interactions, channel isoforms, and other factors

Discussion

Member takes

Implication

Structured PICO

Cite This Study

1,4‐dihydropyridine calcium channel ligands: Selectivity of action. The roles of pharmacokinetics, state‐dependent interactions, channel isoforms, and other factors

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider